{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:00:46Z","timestamp":1773525646754,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.trsl.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T15:47:13Z","timestamp":1517413633000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet"],"prefix":"10.1016","volume":"196","author":[{"given":"Laura","family":"P\u00e9rez-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ochoa-Callejero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Rubio-Mediavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Narro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Antonio","family":"Oteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Ram\u00f3n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.01.004_bib0015","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2018.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/dc07-1526","article-title":"Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects","volume":"31","author":"Musso","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trsl.2018.01.004_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1872-034X.2007.00008.x","article-title":"Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet","volume":"37","author":"Ito","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.trsl.2018.01.004_bib0045","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.lfs.2008.01.022","article-title":"The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice","volume":"82","author":"Cong","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.trsl.2018.01.004_bib0050","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0055","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/hep.23797","article-title":"High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis","volume":"52","author":"Kohli","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0060","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","article-title":"Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis","volume":"179","author":"Itoh","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0065","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI20513","article-title":"Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas","volume":"113","author":"Horie","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0070","article-title":"Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease","volume":"10","author":"Machado","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0075","series-title":"Liver Stiffness (LS) Change in HIV-Hepatitis C (HCV) Coinfected Patients Treated with CCR5 Inhibitor Based Antiretroviral Therapy","author":"Nasta","year":"2011"},{"key":"10.1016\/j.trsl.2018.01.004_bib0080","doi-asserted-by":"crossref","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","article-title":"Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration","volume":"285","author":"Schwabe","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0085","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0090","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2016.08.006","article-title":"Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress","volume":"180","author":"Li","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.trsl.2018.01.004_bib0100","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jhep.2011.04.023","article-title":"RANTES antagonism: a promising approach to treat chronic liver diseases","volume":"55","author":"Affo","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053992","article-title":"Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model","volume":"8","author":"Ochoa-Callejero","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0110","first-page":"678","article-title":"Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression","volume":"6","author":"Stock","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/hep.26403","article-title":"Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice","volume":"58","author":"Barashi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013577","article-title":"Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients","volume":"5","author":"Bertola","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0125","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/db11-1506","article-title":"CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1\/M2 status","volume":"61","author":"Kitade","year":"2012","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.trsl.2018.01.004_bib0130","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1479-5876-9-S1-S9","article-title":"Clinical use of CCR5 inhibitors in HIV and beyond","volume":"9","author":"Gilliam","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.trsl.2018.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/jac\/dku071","article-title":"Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)","volume":"69","author":"Perez-Martinez","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2018.01.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.trsl.2018.01.004_bib0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cts.12397","article-title":"Pharmacokinetics, safety, and CCR2\/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment","volume":"9","author":"Lefebvre","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.trsl.2018.01.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015257","article-title":"Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model","volume":"5","author":"Neff","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.trsl.2018.01.004_bib0170","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.trsl.2018.01.004_bib0175","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jnutbio.2011.11.011","article-title":"Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function","volume":"23","author":"Valdecantos","year":"2012","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0180","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0185","doi-asserted-by":"crossref","DOI":"10.3791\/2710","article-title":"Seven steps to stellate cells","author":"Maschmeyer","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.trsl.2018.01.004_bib0200","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ahj.2007.02.029","article-title":"Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on inflammatory markers study: a substudy of achieve cholesterol targets fast with atorvastatin stratified titration","volume":"153","author":"Blanco-Colio","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.trsl.2018.01.004_bib0205","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0210","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1172\/JCI36066","article-title":"DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation","volume":"120","author":"Koliwad","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0215","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0220","doi-asserted-by":"crossref","first-page":"G852","DOI":"10.1152\/ajpgi.00521.2005","article-title":"Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation","volume":"290","author":"Reddy","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2131\/jts.37.931","article-title":"Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models","volume":"37","author":"Miyashita","year":"2012","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.trsl.2018.01.004_bib0230","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1194\/jlr.M007948","article-title":"Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease","volume":"51","author":"Wang","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2018.01.004_bib0235","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0240","article-title":"Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats","volume":"9","author":"Li","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.01.004_bib0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0250","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M600213-JLR200","article-title":"Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production","volume":"47","author":"Millar","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2018.01.004_bib0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cmet.2007.05.005","article-title":"Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver","volume":"6","author":"Monetti","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.trsl.2018.01.004_bib0260","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI11245","article-title":"Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones","volume":"106","author":"Chao","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0265","doi-asserted-by":"crossref","first-page":"30028","DOI":"10.1074\/jbc.274.42.30028","article-title":"Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus","volume":"274","author":"Shimomura","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0270","doi-asserted-by":"crossref","first-page":"G833","DOI":"10.1152\/ajpgi.90358.2008","article-title":"Resveratrol alleviates alcoholic fatty liver in mice","volume":"295","author":"Ajmo","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0275","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1476-5381.2011.01477.x","article-title":"Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity","volume":"164","author":"Crespillo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0280","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1210\/endo.141.11.7771","volume":"141","author":"Memon","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.trsl.2018.01.004_bib0285","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0290","doi-asserted-by":"crossref","first-page":"19353","DOI":"10.1074\/jbc.M201584200","article-title":"Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)\/Lep(ob) mice","volume":"277","author":"Yahagi","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0295","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0300","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.01.004_bib0305","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1172\/JCI23187","article-title":"Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism","volume":"115","author":"Taniguchi","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.01.004_bib0310","doi-asserted-by":"crossref","first-page":"E897","DOI":"10.1152\/ajpendo.00177.2013","article-title":"Loss of CCR5 results in glucose intolerance in diet-induced obese mice","volume":"305","author":"Kennedy","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.trsl.2018.01.004_bib0315","first-page":"675","article-title":"Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation","volume":"3","author":"Kirovski","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.trsl.2018.01.004_bib0320","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2337\/db10-0224","article-title":"Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL\/6 mice","volume":"59","author":"Duval","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.trsl.2018.01.004_bib0325","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.cyto.2012.12.013","article-title":"Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation","volume":"61","author":"Diaz-Delfin","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.trsl.2018.01.004_bib0330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3851\/IMP3099","article-title":"Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity","volume":"22","author":"Perez-Matute","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2018.01.004_bib0335","doi-asserted-by":"crossref","first-page":"21240","DOI":"10.3390\/ijms141121240","article-title":"Lessons from mouse models of high-fat diet-induced NAFLD","volume":"14","author":"Nakamura","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2018.01.004_bib0340","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.3390\/ijms140611963","article-title":"In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD)","volume":"14","author":"Kanuri","year":"2013","journal-title":"Int J Mol Sci"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T17:55:51Z","timestamp":1603734951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":65,"alternative-id":["S1931524418300069"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.01.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}